Latham & Watkins Advises on Artiva Biotherapeutics’ US$300 Million Offering of Common Stock and Pre‑Funded Warrants

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical‑stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with debilitating autoimmune diseases, announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of US$11.52 per share and, in lieu of shares of common stock to certain investors, pre‑funded warrants to purchase 2,170,138 shares of common stock at a purchase price of US$11.5199 per share, which equals the offering price per share of the common stock less the US$0.0001 exercise price per share of each pre‑funded warrant. All of the shares of common stock and pre‑funded warrants in the offering are being sold by Artiva. The offering is expected to close on or about May 11, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by San Diego partner Matt Bush, with associates Omeed Valipour, Rachel Staub, and Madeline Hodges.